Impact of TP53 Mutations and MDM2 Genotype in Breast Cancer Treatment
Author Information
Author(s): Chrisanthar Ranjan, Knappskog Stian, Løkkevik Erik, Anker Gun, Østenstad Bjørn, Lundgren Steinar, Risberg Terje, Mjaaland Ingvil, Skjønsberg Gudbrand, Aas Turid, Schlichting Ellen, Fjösne Hans E., Nysted Arne, Lillehaug Johan Richard, Lønning Per Eystein
Primary Institution: University of Bergen, Bergen, Norway
Hypothesis
The study investigates the predictive and prognostic value of TP53 and CHEK2 mutation status along with MDM2 SNP309 genotype in breast cancer patients receiving paclitaxel or epirubicin.
Conclusion
TP53 and CHEK2 mutations were linked to poor response to epirubicin, while TP53 mutations and MDM2 309G allele status were associated with worse disease-specific survival in patients treated with paclitaxel.
Supporting Evidence
- TP53 mutations were found in 21.5% of patients.
- Patients with TP53 mutations had a significant reduction in disease-specific survival when treated with paclitaxel.
- MDM2 SNP309 genotype was associated with disease-specific survival outcomes.
- Patients receiving second-line therapy showed different response rates compared to first-line treatment.
Takeaway
This study found that certain gene mutations can affect how well breast cancer patients respond to chemotherapy, helping doctors choose better treatments.
Methodology
Patients were randomly assigned to receive either epirubicin or paclitaxel as monotherapy, with tumor tissue samples collected for genetic analysis.
Potential Biases
Potential biases may arise from the open-label design and patient selection criteria.
Limitations
The study may not account for all variables affecting treatment response and survival, and some patients were switched to second-line therapy.
Participant Demographics
Median age was 51 years, with a range of 25 to 70 years; 223 patients with primary stage III breast cancer were enrolled.
Statistical Information
P-Value
p=0.007 for TP53 mutations and p=0.012 for MDM2 genotype status related to survival.
Confidence Interval
95% CI for MDM2 SNP309 TG/GG status was 1.152–3.610.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website